Nyxoah presents 12-month data for sleep apnea device study
Nyxoah SA (NYXH) presented 12-month data from its ACCCESS study on the Genio system for sleep apnea, meeting efficacy endpoints. AHI responder rate was 77.2%, ODI 87.7%. No device-related serious adverse events occurred. The company submitted a PMA supplement to the FDA to expand the Genio system's indication.
How this was made
The 30-second read
Why it matters
The disclosed 12-month pivotal outcomes and same-day FDA premarket approval supplement submission are the key catalysts, potentially increasing the probability of expanding the U.S. indication.
Market read
Traders may reprice NYXH on improved regulatory prospects tied to pivotal 12-month efficacy and safety plus an FDA filing step.
What to watch
The article does not quantify label-expansion timing, FDA review outcome, or commercial uptake assumptions; traders may need to discount near-term price action until FDA feedback or additional subgroup analyses emerge.
Background
Nyxoah’s Genio system received FDA approval in August 2025 and CE Mark approval in 2019; the ACCCESS U.S. pivotal study targets obstructive sleep apnea with complete concentric collapse.
Ticker impact
Nyxoah reported complete 12-month ACCCESS U.S. pivotal results for its Genio hypoglossal nerve stimulation system and said both co-primary endpoints were met.
Likely upward bias as traders price in higher odds of FDA label expansion and stronger adoption for complete concentric collapse patients.
The article discloses responder rates, AHI/ODI reductions, absence of device/procedure-related serious adverse events through 12 months, and that an FDA supplement was submitted the same day.
Market effects
Supports sentiment for neurostimulation and sleep apnea device peers by reinforcing the clinical viability of hypoglossal nerve stimulation in a previously underserved patient subgroup.
Limited direct regional spillover, but could attract incremental attention to European medtech with U.S. regulatory momentum.
Moderate global relevance for sleep apnea treatment markets, especially where complete concentric collapse patients lack neurostimulation options.
Counterpoint
Responder rates and AHI/ODI improvements may already be partially anticipated by the market, so the incremental impact could be muted if investors focus on remaining FDA review timelines and commercial execution risks.
Key entities
- companyNyxoah SA
Subject of the article, presenting 12-month ACCCESS U.S. pivotal study results for Genio and submitting an FDA supplement to expand indication.
- productGenio system
Bilateral hypoglossal nerve stimulation device evaluated in the ACCCESS study for obstructive sleep apnea with complete concentric collapse.
- regulatorU.S. Food and Drug Administration
Received a premarket approval supplement submission today to expand Genio’s indication.
